CVS – CVS Health Corporation

CVS Health Corporation: Monthly Stock Report – December 03, 2025

Company Overview

CVS Health Corporation, headquartered in Woonsocket, Rhode Island, is a prominent player in the healthcare sector, particularly within the Healthcare Plans industry. The company operates through three primary segments: Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness.

• Health Care Benefits: This segment provides an array of health insurance products and services, including medical and prescription plans for various customer groups–employers, individuals, and government units.
• Health Services: CVS Health focuses on pharmacy benefit management solutions designed for employers and health plans.
• Pharmacy & Consumer Wellness: This arm markets prescription medications, over-the-counter drugs, and personal care products directly to consumers.

Formerly known as CVS Caremark Corporation, the company rebranded in September 2014. With a total revenue of approximately $391.7 billion, CVS Health exhibits strong financial health bolstered by a diverse business model. The anticipated growth and stability within the healthcare sector underpin a “buy” recommendation, with a target high price set at $102, reflecting confidence in the company’s ability to deliver shareholder value amidst the complexities of the healthcare landscape.

52-Week Price Performance Analysis

The stock price for CVS Health, as of December 3, 2025, stands at $76.47, indicating a notable decline from its 52-week high of $85.15 while remaining above its 52-week low of $43.56. This volatility hints at key trends in investor behavior and market dynamics.

Trend Analysis

• Bullish Momentum: Over the past year, CVS Health’s stock has surged by 39.43% since its lows in December and January, driven by consistently higher highs and higher lows. The stock price has articulated a strong upward trend as evidenced by the upward-sloping green trendline visible on the 52-week chart.

• Support and Resistance Levels: Key price levels can be identified through the chart. The red dashed line at around $50 serves as a robust support level that was tested multiple times earlier in the year, reinforcing a solid base for the current upward trend. On the upper end, the resistance level nears $80, which the stock approached but has yet to surpass decisively.

• Moving Averages: The stock is currently trading slightly below its fifty-day moving average of $78.65, indicating a slight consolidation phase. However, continual crossings above this average in recent months suggest strong momentum and alignment with the broader uptrend.

Price Action and Outlook

A slight pullback has occurred recently from highs in November to early December. However, maintaining levels above the long-term trendline and moving average suggests a healthy retracement within an ongoing bullish framework. This indicates potential for a breakout above the established resistance, supporting growth prospects ahead.

Financial Performance and Metrics

CVS Health’s financial performance showcases its operational strength and market viability:

• Total Revenue: Approximately $391.69 billion, demonstrating robust performance driven primarily by a diverse service offering.
• EBITDA: The company boasts an EBITDA of around $14.75 billion, reflecting solid profitability and operational efficiency.
• Dividend Declaration: On November 3, 2025, CVS announced a quarterly dividend of $0.665 per share, further reassuring investors of its commitment to returning value.

In terms of valuation metrics, CVS Health’s stock has experienced a substantial growth rate, with a current price of $76.47 that remains below the target mean price of $91.48. The confidence in this valuation is evident with a calculated high target price of $102 based on current financial data.

Recent News and Developments

CVS Health has faced some challenges amid significant news developments:

• Settlement Agreement: Recently, CVS agreed to a $37.76 million settlement stemming from allegations that they improperly dispensed insulin pens and collected reimbursements from government programs between 2010-2020. This settlement includes $24.45 million to the federal government, and reflects the scrutiny under which CVS operates in the healthcare sector. (Source)

• Recent Executive Changes: In October 2024, CVS Health appointed David Joyner as the new president and CEO, succeeding Karen S. Lynch amid investor pressures over stock performance. This leadership change is pivotal for the future direction of the company. (Source)

• Earnings Report: Analysts remain bullish following CVS Health’s third-quarter revenue report that reached $102.9 billion, reflecting a 7.8% year-on-year increase. This positive earnings announcement has led TD Cowen to raise its price target to $100. (Source)

Market Sentiment and Analyst Recommendations

In light of recent trends, the market sentiment surrounding CVS Health has exhibited a strongly positive outlook:

• Analyst Consensus: A total of 25 analysts have weighed in, resulting in a recommendation mean of approximately 1.57, which underlines the bullish sentiment towards the stock.

• Price Targets: The analysts suggest a target price range with a high of $102, indicating that considerable appreciation potential exists given the current share price.

• Low Short Interest: With approximately only 1.54% of the float shorted, investor confidence appears stable, suggesting that the market does not anticipate drastic declines in CVS Health’s stock performance in the near term.

Conclusion

CVS Health Corporation stands at a pivotal juncture with potential for growth driven by its robust business model and strategic market positioning. Current financial performance, combined with a positive analyst outlook and manageable levels of investor risk signals, holds promise for retail investors seeking to capitalize on market momentum. While navigating challenges, including legal scrutiny and leadership changes, CVS Health’s proactive strategies appear well-aligned with future opportunities in the expansive healthcare market. As a final recommendation, CVS stock is poised for a buy, creating an advantageous entry point with a focus on long-term growth potential.

Metric	Value
Market Cap	$97.1b
Total Debt	$81.8b
Total Cash	$11.2b
Shares Outstanding	1.3b
Float Shares	1.3b